Erythropoietin for patients with malignant disease - PubMed
Review
Erythropoietin for patients with malignant disease
J Bohlius et al. Cochrane Database Syst Rev. 2004.
Update in
-
Erythropoietin or darbepoetin for patients with cancer.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Bohlius J, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003407. doi: 10.1002/14651858.CD003407.pub4. Cochrane Database Syst Rev. 2006. PMID: 16856007 Updated. Review.
Abstract
Background: Anaemia associated with cancer and cancer therapy is an important clinical factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant human erythropoietin (EPO) and red blood cell transfusions.
Objectives: The aim of this systematic review was to assess the effect of erythropoietin to either prevent or treat anaemia in cancer patients.
Search strategy: We searched the Central Register of Controlled Trials, MEDLINE (01/1985 to 12/2001), EMBASE (01/1985 to 12/2001), other databases and reference lists of articles. We also contacted experts in the field and pharmaceutical companies.
Selection criteria: Randomised controlled trials comparing the use of recombinant human erythropoietin (plus transfusion if needed) with red blood cell transfusions alone for the treatment or prevention of anaemia in cancer patients.
Data collection and analysis: Two reviewers independently assessed trial quality and extracted data. All authors from included studies were contacted for additional information.
Main results: Twenty seven trials with 3,287 adults were included. Use of erythropoietin significantly reduced the relative risk of red blood cell transfusions (RR 0.67; 95% CI 0.62 to 0.73, 25 trials, n = 3,069). On average participants in the erythropoietin group received one unit of blood less than the control group (WMD -1.00; 95% CI-1.31 to -0.70, 13 trials, n = 2,056). For participants with baseline haemoglobin below 10 g/dL haematological response was observed more often in participants receiving EPO (RR 3.60; 95% CI 3.07 to 4.23, 14 trials, n = 2,347). There was inconclusive evidence whether EPO improves tumour response (fixed effect RR 1.36; 95% CI 1.07 to 1.72, seven trials, n = 1,150; random effects: RR 1.21; 95% CI 0.92 to 1.59) and overall survival (adjusted data: HR 0.81; 95% CI 0.67 to 0.99; unadjusted data: HR 0.84; 95% CI 0.69 to 1.02, 19 trials, n = 2,865). There were no statistically significant adverse effects. Evidence was inconclusive with respect to quality of life and fatigue.
Reviewers' conclusions: There is consistent evidence that the administration of erythropoietin reduces the risk for blood transfusions and the number of units transfused in cancer patients. For patients with baseline haemoglobin below 10 g/dL there is strong evidence that erythropoietin improves haematological response. There is inconclusive evidence whether erythropoietin improves tumour response and overall survival. Research on side effects is inconclusive.
Similar articles
-
Erythropoietin or darbepoetin for patients with cancer.
Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert E. Bohlius J, et al. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003407. doi: 10.1002/14651858.CD003407.pub4. Cochrane Database Syst Rev. 2006. PMID: 16856007 Updated. Review.
-
Erythropoietin or darbepoetin for patients with cancer.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Tonia T, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5. Cochrane Database Syst Rev. 2012. PMID: 23235597 Free PMC article. Review.
-
Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C. Wilson J, et al. Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130. Health Technol Assess. 2007. PMID: 17408534 Review.
-
Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Pennington S, Vale L, Wallace S, MacLeod A. Cody J, et al. Cochrane Database Syst Rev. 2001;(4):CD003266. doi: 10.1002/14651858.CD003266. Cochrane Database Syst Rev. 2001. PMID: 11687180 Updated. Review.
-
Cody J, Daly C, Campbell M, Donaldson C, Grant A, Khan I, Vale L, Wallace S, MacLeod A. Cody J, et al. Cochrane Database Syst Rev. 2002;(4):CD003895. doi: 10.1002/14651858.CD003895. Cochrane Database Syst Rev. 2002. PMID: 12519614 Updated. Review.
Cited by
-
Geiser F, Hahn C, Conrad R, Liedtke R, Sauerbruch T, Schmidt-Wolf I, Glasmacher A. Geiser F, et al. Support Care Cancer. 2007 Mar;15(3):273-8. doi: 10.1007/s00520-006-0132-8. Epub 2006 Aug 25. Support Care Cancer. 2007. PMID: 16932973
-
Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Aapro M, et al. Front Pharmacol. 2019 Jan 9;9:1498. doi: 10.3389/fphar.2018.01498. eCollection 2018. Front Pharmacol. 2019. PMID: 30687083 Free PMC article. Review.
-
Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Aapro M, et al. Br J Cancer. 2006 Dec 4;95(11):1467-73. doi: 10.1038/sj.bjc.6603481. Epub 2006 Nov 21. Br J Cancer. 2006. PMID: 17117175 Free PMC article.
-
Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P; EPO-INT-45 Study Group. Wilkinson PM, et al. Br J Cancer. 2006 Apr 10;94(7):947-54. doi: 10.1038/sj.bjc.6603004. Br J Cancer. 2006. PMID: 16570051 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials